Recently, TOX was revealed its crucial role in tumor‐specific T cell differentiation and CD8+ T cell exhaustion, highlighting a potential biomarker for response prediction or enhancement of cancer immunotherapy.21, 22. This evidence concerns the gene CD8A and neoplasm.